Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.

Chen A, Wright H, Itana H, Elahi M, Igun A, Soon G, Pariser AR, Fadiran EO.

J Womens Health (Larchmt). 2018 Apr;27(4):418-429. doi: 10.1089/jwh.2016.6272. Epub 2017 Oct 19.

PMID:
29048983
2.

A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins.

Rosenberg AS, Pariser AR, Diamond B, Yao L, Turka LA, Lacana E, Kishnani PS.

Clin Immunol. 2016 Apr;165:55-9. doi: 10.1016/j.clim.2016.02.009. Epub 2016 Feb 27. Review.

PMID:
26928739
3.

Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.

Lapteva L, Pariser AR.

J Investig Med. 2016 Feb;64(2):376-82. doi: 10.1136/jim-2015-000010.

PMID:
26911627
4.

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.

Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR.

Mol Genet Metab. 2016 Feb;117(2):66-83. doi: 10.1016/j.ymgme.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26597321
5.

Important role of translational science in rare disease innovation, discovery, and drug development.

Pariser AR, Gahl WA.

J Gen Intern Med. 2014 Aug;29 Suppl 3:S804-7. doi: 10.1007/s11606-014-2881-2.

6.

Phenylketonuria Scientific Review Conference: state of the science and future research needs.

Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates PM, Cunningham AC, Dobrowolski SF, Ferguson JH, Franklin TD, Frazier DM, Grange DK, Greene CL, Groft SC, Harding CO, Howell RR, Huntington KL, Hyatt-Knorr HD, Jevaji IP, Levy HL, Lichter-Konecki U, Lindegren ML, Lloyd-Puryear MA, Matalon K, MacDonald A, McPheeters ML, Mitchell JJ, Mofidi S, Moseley KD, Mueller CM, Mulberg AE, Nerurkar LS, Ogata BN, Pariser AR, Prasad S, Pridjian G, Rasmussen SA, Reddy UM, Rohr FJ, Singh RH, Sirrs SM, Stremer SE, Tagle DA, Thompson SM, Urv TK, Utz JR, van Spronsen F, Vockley J, Waisbren SE, Weglicki LS, White DA, Whitley CB, Wilfond BS, Yannicelli S, Young JM.

Mol Genet Metab. 2014 Jun;112(2):87-122. doi: 10.1016/j.ymgme.2014.02.013. Epub 2014 Mar 6.

PMID:
24667081
7.

Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases.

Fiorentino R, Liu G, Pariser AR, Mulberg AE.

J Allergy Clin Immunol. 2012 Sep;130(3):613-6. doi: 10.1016/j.jaci.2012.07.011. Epub 2012 Jul 31.

PMID:
22857796
8.

Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.

Pariser AR, Slack DJ, Bauer LJ, Warner CA, Tracy LA.

Drug Discov Today. 2012 Aug;17(15-16):898-904. doi: 10.1016/j.drudis.2012.04.011. Epub 2012 May 5.

PMID:
22564486
9.

The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.

Lacaná E, Yao LP, Pariser AR, Rosenberg AS.

Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):30-9. doi: 10.1002/ajmg.c.31316. Epub 2012 Jan 17.

PMID:
22253234
10.

Clinical pharmacology as a cornerstone of orphan drug development.

Bashaw ED, Huang SM, Coté TR, Pariser AR, Garnett CE, Burckart G, Zhang L, Men AY, Le CD, Charlab R, Gobburu JV, Lesko LJ.

Nat Rev Drug Discov. 2011 Oct 31;10(11):795-6. doi: 10.1038/nrd3595.

PMID:
22037026
11.
12.

Research challenges in central nervous system manifestations of inborn errors of metabolism.

Dickson PI, Pariser AR, Groft SC, Ishihara RW, McNeil DE, Tagle D, Griebel DJ, Kaler SG, Mink JW, Shapiro EG, Bjoraker KJ, Krivitzky L, Provenzale JM, Gropman A, Orchard P, Raymond G, Cohen BH, Steiner RD, Goldkind SF, Nelson RM, Kakkis E, Patterson MC.

Mol Genet Metab. 2011 Mar;102(3):326-38. doi: 10.1016/j.ymgme.2010.11.164. Epub 2010 Dec 2. Review.

13.

Accelerating orphan drug development.

Coté TR, Xu K, Pariser AR.

Nat Rev Drug Discov. 2010 Dec;9(12):901-2. doi: 10.1038/nrd3340.

PMID:
21119719
14.

Therapies for inborn errors of metabolism: what has the orphan drug act delivered?

Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR.

Pediatrics. 2010 Jul;126(1):101-6. doi: 10.1542/peds.2009-3246. Epub 2010 Jun 21.

PMID:
20566615

Supplemental Content

Loading ...
Support Center